Immix Biopharma director gets RSU, option grants

Immix Biopharma director Yekaterina Chudnovsky reported equity awards and updated holdings.

Rhea-AI Filing Summary

Immix Biopharma director Yekaterina Chudnovsky reported equity awards and updated holdings. She received 6,250 restricted stock units under the 2021 Equity Incentive Plan, vesting in full on the earlier of one year from grant or the 2027 annual stockholders meeting, subject to continued service.

She was also granted stock options for 12,500 shares of common stock at an exercise price of $8.78 per share, vesting in substantially equal monthly installments over 12 months or, if earlier, on the date of the 2027 annual meeting, contingent on continued board service. Following this Form 4, she holds 6,250 common shares directly and 12,500 options, and is associated with 3,241,076 shares held indirectly by GKCC, LLC, where she is the sole member and manager.

Insights

Equity compensation analyst

Routine director equity grants with time-based vesting and large pre-existing indirect holdings.

The Form 4 shows Yekaterina Chudnovsky, a director of Immix Biopharma, receiving 6,250 RSUs and 12,500 stock options at $8.78 per share. Both awards vest on time-based schedules tied to continued board service and the 2027 annual stockholders meeting.

These are standard governance-aligned awards, compensating a non-employee director in equity rather than cash. The filing also notes 3,241,076 common shares held indirectly by GKCC, LLC, an entity she manages and may be deemed to beneficially own, indicating a substantial existing economic stake.

Because the awards are grants, not market purchases or sales, they carry limited signaling value for near-term stock sentiment. They mainly adjust the mix and structure of director compensation and confirm ongoing alignment between the director’s interests and shareholders through equity exposure.

Insider Trade Summary

Grant/Award: 18,750 shares

Grant/Award 3 txns

Insider Chudnovsky Yekaterina

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	12,500	$0.00	$0.00
Grant/Award	Common Stock	6,250	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 12,500 contracts (Direct); Common Stock — 6,250 shares (Direct); Common Stock — 3,241,076 shares (Indirect, Held by GKCC, LLC)

Footnotes (3)

1. F1. The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
2. F2. The Reporting Person is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.
3. F3. The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

Key Figures

RSU grant: 6,250 shares Stock options granted: 12,500 options Option exercise price: $8.78 per share +3 more

6 metrics

RSU grant 6,250 shares Restricted stock units granted to director on May 22, 2026

Stock options granted 12,500 options Options on common stock granted on May 22, 2026

Option exercise price $8.78 per share Exercise price for 12,500 stock options

Indirect holdings via GKCC, LLC 3,241,076 shares Common stock held indirectly as of May 22, 2026

Direct common stock after grant 6,250 shares Total direct common shares following RSU grant

Option expiration May 22, 2036 Expiration date of 12,500 stock options

Key Terms

restricted stock units, 2021 Equity Incentive Plan, stock option, beneficially own, +1 more

5 terms

restricted stock units financial

"The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2021 Equity Incentive Plan financial

"6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan"

stock option financial

"The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

beneficially own financial

"may be deemed to beneficially own the shares held by GKCC, LLC"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

vesting financial

"which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What equity awards did Immix Biopharma (IMMX) director Yekaterina Chudnovsky receive?

She received 6,250 restricted stock units and stock options for 12,500 shares of Immix Biopharma common stock. Both awards were granted at no cash cost, with vesting tied to service and the company’s 2027 annual stockholders meeting.

When do Yekaterina Chudnovsky’s new Immix Biopharma RSUs vest?

The 6,250 RSUs vest in full on the earlier of one year from the grant date or the 2027 annual stockholders meeting. Vesting is conditioned on her continued service with Immix Biopharma through the applicable vesting date.

What are the terms of the new Immix Biopharma stock options granted to Chudnovsky?

She was granted options for 12,500 shares at an exercise price of $8.78 per share. These options vest in substantially equal monthly installments over 12 months or fully on the 2027 annual meeting date, subject to continued board service.

How many Immix Biopharma shares does GKCC, LLC hold in connection with Chudnovsky?

GKCC, LLC holds 3,241,076 Immix Biopharma common shares. Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares that the entity holds, according to the Form 4 footnote.

Are Chudnovsky’s recent Immix Biopharma transactions open-market buys or sells?

No, the Form 4 reflects equity compensation grants, not open-market trades. She received 6,250 RSUs and 12,500 stock options as awards, with no reported open-market purchases or sales of Immix Biopharma common stock in this filing.

Under which plan were Yekaterina Chudnovsky’s new Immix Biopharma RSUs granted?

The 6,250 RSUs were granted pursuant to Immix Biopharma’s 2021 Equity Incentive Plan. The plan provides for equity-based compensation, and these RSUs will vest based on time and the timing of the company’s 2027 annual stockholders meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 05:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chudnovsky Yekaterina

(Last) (First) (Middle)

C/O IMMIX BIOPHARMA, INC.

11400 WEST OLYMPIC BLVD., SUITE 200

(Street)

LOS ANGELES CALIFORNIA 90064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/22/2026		A		6,250(1)	A	$0	6,250	D
Common Stock								3,241,076	I	Held by GKCC, LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.78	05/22/2026		A		12,500		(3)	05/22/2036	Common Stock	12,500	$0	12,500	D

Explanation of Responses:

1. The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.

2. The Reporting Person is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

3. The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

Remarks:

Exhibit 24.1 - Powers of Attorney

	/s/ Ilya Rachman as Attorney-In-Fact for Yekaterina Chudnovsky	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)